Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD
Comparison of a Serum Procalcitonin (PRO-CT) Guided Treatment Plan With the Standard Guideline Recommended Antibiotic Treatment Plan for Patients Hospitalized With a Diagnosis of Exacerbation of COPD
Sponsor: Agenzia Italiana del Farmaco
Listed as NCT01125098, this observational or N/A phase trial focuses on Chronic Obstructive Pulmonary Disease and remains completed. Sponsored by Agenzia Italiana del Farmaco, it has been updated 12 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Dec 2021 — Dec 2022 [monthly]
Completed
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agenzia Italiana del Farmaco
- University of Modena and Reggio Emilia
For direct contact, visit the study record on ClinicalTrials.gov .